AI Maverick Intel, Inc. (AIMV)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AI Maverick Intel, Inc. (AIMV) trades at $0.13 with AI Score 58/100 (Grade B). AI Maverick Intel, Inc. Market cap: $6.57M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for AIMV: AIMV does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AIMV against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
AIMV: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI Maverick Intel, Inc. (AIMV) Healthcare & Pipeline Overview
AI Maverick Intel, Inc. leverages its proprietary AI Maverick platform to enhance businesses, focusing on automated customer acquisition and data-driven engagement. Targeting healthcare and biotech sectors, the company streamlines communication processes. Formerly Bionoid Pharma Inc., AI Maverick Intel, Inc. aims to optimize business operations through artificial intelligence.
What Is the Investment Thesis for AIMV?
AI Maverick Intel, Inc. presents a high-risk, high-reward investment opportunity given its early stage and focus on AI-driven business enhancement. The company's value proposition hinges on the effectiveness and scalability of its AI Maverick platform in streamlining customer acquisition and engagement. Key value drivers include the platform's adoption rate among healthcare and biotech clients, its ability to generate measurable improvements in client performance metrics, and the company's success in acquiring and integrating new businesses. With a market capitalization of $6.57M and a negative P/E ratio of -3.51, the company's valuation is speculative and dependent on future growth. The extremely high profit margin of 7728.5% and gross margin of 6289.2% may be due to one-off events or accounting anomalies, and should be viewed with caution. The company's beta of -5.11 suggests an inverse correlation with the market, which may be misleading given its limited trading history and OTC status. The absence of a dividend reflects its focus on reinvesting earnings for growth. Investors should carefully assess the company's ability to execute its business plan, navigate the competitive landscape, and achieve sustainable profitability.
Based on FMP financials and quantitative analysis
AIMV Key Highlights
- Market Cap of $6.57M indicates a micro-cap valuation, reflecting the company's early stage and potential for high growth or significant risk.
- P/E Ratio of -3.51 suggests the company is currently unprofitable, requiring further investigation into its earnings potential and path to profitability.
- Profit Margin of 7728.5% is exceptionally high and may be due to non-recurring items or accounting anomalies, warranting a detailed review of the company's financial statements.
- Gross Margin of 6289.2% also appears unusually high, indicating a potential competitive advantage or unsustainable pricing strategy.
- Beta of -5.11 suggests an inverse correlation with the market, but may not be reliable due to the company's limited trading history and OTC status.
Who Are AIMV's Competitors?
AIMV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AIMV's Key Strengths?
- Proprietary AI Maverick platform
- Focus on high-growth healthcare and biotech sectors
- Data-driven approach to customer acquisition
- Potential for scalability through strategic partnerships
What Are AIMV's Weaknesses?
- Small team size (5 employees) limits operational capacity
- Limited financial resources due to micro-cap status
- Dependence on the success of the AI Maverick platform
- Lack of established brand recognition
What Could Drive AIMV Stock Higher?
- Successful implementation of the AI Maverick platform with new healthcare and biotech clients, demonstrating tangible improvements in their customer acquisition metrics.
- Expansion of the AI Maverick platform's capabilities to include advanced data analytics and insights services, attracting new clients and increasing revenue streams.
- Strategic partnerships with complementary technology providers or acquisitions of companies with established customer bases, accelerating growth and market reach.
What Are the Key Risks for AIMV?
- Negative return on equity (-14.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from established technology companies and specialized AI vendors may limit AI Maverick Intel, Inc.'s market share and pricing power.
- Rapid technological advancements in the AI space may render the AI Maverick platform obsolete, requiring significant investments in research and development.
- Regulatory changes in the healthcare and biotech sectors may impact the company's ability to operate and serve its clients.
- The company's small team size and limited financial resources may constrain its ability to execute its business plan and compete effectively.
- The company's OTC Other listing and lack of financial disclosure increase the risk of fraud, manipulation, and loss of investment.
What Are the Growth Opportunities for AIMV?
- AI-Driven Customer Acquisition: AI Maverick Intel, Inc. can capitalize on the growing demand for AI-powered customer acquisition solutions in the healthcare and biotech sectors. The market for AI in customer relationship management (CRM) is projected to reach $37.9 billion by 2027. By leveraging its AI Maverick platform, the company can help healthcare and biotech firms identify and engage with their ideal audience segments more effectively, leading to increased sales and market share. This opportunity is ongoing as companies seek to improve their customer acquisition strategies.
- Expansion into New Verticals: While currently focused on healthcare and biotech, AI Maverick Intel, Inc. can expand its AI Maverick platform to other sectors with similar customer acquisition challenges, such as financial services, e-commerce, and education. The broader market for AI in enterprise applications is estimated to reach $50 billion by 2028. By adapting its platform to meet the specific needs of these new verticals, the company can diversify its revenue streams and reduce its reliance on the healthcare and biotech sectors. This expansion could begin within the next 12-18 months.
- Strategic Partnerships and Acquisitions: AI Maverick Intel, Inc. can pursue strategic partnerships and acquisitions to expand its technology portfolio, market reach, and talent pool. Collaborating with complementary technology providers or acquiring companies with established customer bases can accelerate its growth trajectory. The market for mergers and acquisitions in the AI space is highly active, with numerous opportunities to acquire innovative technologies and expand market presence. This strategy is ongoing as the company seeks to enhance its capabilities and market position.
- Data Analytics and Insights: The AI Maverick platform can be further developed to provide advanced data analytics and insights to its clients. By analyzing customer data and market trends, the company can help healthcare and biotech firms make more informed decisions about product development, marketing campaigns, and sales strategies. The market for AI-powered data analytics is projected to reach $45 billion by 2025. This opportunity is ongoing as companies seek to leverage data to gain a competitive edge.
- Regulatory Compliance Solutions: AI Maverick Intel, Inc. can develop AI-powered solutions to help healthcare and biotech firms comply with complex regulatory requirements, such as HIPAA and GDPR. The increasing complexity of regulations and the growing risk of non-compliance are driving demand for automated compliance solutions. By leveraging its AI platform, the company can help its clients streamline their compliance processes, reduce their risk of penalties, and improve their overall operational efficiency. This opportunity is ongoing as regulatory requirements continue to evolve.
What Opportunities Does AIMV Have?
- Expansion into new verticals beyond healthcare and biotech
- Development of advanced data analytics and insights services
- Strategic partnerships and acquisitions to expand market reach
- Growing demand for AI-powered solutions in various industries
What Threats Does AIMV Face?
- Intense competition from established technology companies
- Rapid technological advancements may render the AI Maverick platform obsolete
- Regulatory changes in the healthcare and biotech sectors
- Economic downturn may reduce demand for AI-driven solutions
What Are AIMV's Competitive Advantages?
- Proprietary AI Maverick platform provides a technological advantage.
- Focus on the healthcare and biotech sectors allows for specialized expertise.
- Data-driven approach enables more effective customer engagement.
- Potential for network effects as more businesses join the platform.
What Does AIMV Do?
AI Maverick Intel, Inc., formerly known as Bionoid Pharma Inc., was incorporated in 2006 and is headquartered in Beverly Hills, California. The company rebranded in April 2025 to reflect its strategic shift towards artificial intelligence-driven solutions. AI Maverick Intel, Inc. operates as an AI company focused on acquiring and enhancing businesses through its proprietary AI Maverick platform. The platform is designed to streamline the customer acquisition process by automating two-way communication and enabling data-driven engagement with ideal audience segments. The company primarily targets clients within the healthcare and biotech sectors, aiming to improve their operational efficiency and market reach through AI-powered tools. AI Maverick Intel, Inc.'s business model centers around leveraging its AI technology to optimize various business functions, particularly in customer relationship management and data analytics. The company's small team of five employees indicates a lean operational structure, potentially relying on strategic partnerships or outsourced services to support its technology development and client engagements. The company's transformation from Bionoid Pharma Inc. highlights a strategic pivot towards capitalizing on the growing demand for AI solutions across diverse industries.
What Products and Services Does AIMV Offer?
- Acquires and enhances businesses through its AI platform.
- Streamlines customer acquisition processes.
- Automates two-way communication with potential customers.
- Enables data-driven engagement with target audiences.
- Focuses on the healthcare and biotech sectors.
- Leverages AI to optimize business operations.
- Provides AI-powered solutions for customer relationship management.
How Does AIMV Make Money?
- Acquires businesses with growth potential.
- Implements its AI Maverick platform to enhance acquired businesses.
- Generates revenue through improved efficiency and increased sales of acquired businesses.
- Potentially offers its AI platform as a service to other companies.
What Industry Does AIMV Operate In?
AI Maverick Intel, Inc. operates within the rapidly evolving healthcare and biotech sectors, where AI is increasingly being adopted to enhance various business processes, from customer acquisition to data analytics. The market for AI in healthcare is projected to reach billions of dollars in the coming years, driven by the need for improved efficiency, personalized medicine, and cost reduction. The competitive landscape includes established technology companies, specialized AI vendors, and other firms offering AI-driven solutions for healthcare and biotech. AI Maverick Intel, Inc. aims to differentiate itself through its proprietary AI Maverick platform, focusing on streamlining customer acquisition and engagement.
Who Are AIMV's Key Customers?
- Healthcare companies seeking to improve customer acquisition.
- Biotech firms looking to enhance their marketing and sales efforts.
- Businesses in other sectors with similar customer acquisition challenges.
- Companies seeking to leverage AI for data-driven decision-making.
AI Maverick Intel, Inc. (AIMV) Valuation Context
Valued at $6.57M, AIMV is classified as a micro-cap stock. Relative to its peer group, AIMV's quantitative score of 58/100 is below the peer average of 69/100.
AIMV Revenue & Earnings Trend
In Q2 2025, AIMV generated $0 in top-line revenue. The company recorded a net loss of $210K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, AIMV averaged $-0.00 in diluted EPS.
Company Profile
AI Maverick Intel, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Beverly Hills, US. The company is led by CEO Patricia Colvin. AIMV has traded publicly since 2007.
ROE -15%Key Financial Metrics
Return on equity for AI Maverick Intel, Inc. stands at -14.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -14.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -10.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
AI Maverick Intel, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 8.72 places it in the safe zone, indicating low near-term bankruptcy risk.
AIMV Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that management believes in the potential for growth.
- Community sentiment has shifted positively, with discussions highlighting innovative developments in AI technology that AIMV is pursuing.
- Increased media coverage has drawn attention to AIMV's unique approach to AI solutions, enhancing its visibility among investors.
- Positive feedback from industry analysts emphasizes AIMV's potential to disrupt traditional markets with its cutting-edge technology.
Bear Case
- Concerns about the competitive landscape in the AI sector are growing, with several established players ramping up their efforts, potentially overshadowing AIMV.
- Social sentiment has shown some skepticism, with discussions around the company's ability to scale its operations effectively in a rapidly evolving market.
- Recent earnings reports have raised questions about AIMV's revenue generation capabilities, leading to doubts about its immediate financial health.
- Some community members express concerns over the sustainability of AIMV's current business model, suggesting it may not withstand economic fluctuations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $0 | -$210,379 | -$0.0039 |
| Q1 2025 | $0 | -$247,000 | -$0.0046 |
| Q4 2024 | -$20,941 | -$128,000 | -$0.0024 |
| Q3 2024 | $10,983 | -$184,229 | -$0.0034 |
Based on FMP financials and quantitative analysis
AIMV Latest News
No recent news available for AIMV.
AIMV Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AIMV.
Price Targets
Wall Street price target analysis for AIMV.
AIMV MoonshotScore
What does this score mean?
The MoonshotScore rates AIMV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Patricia Colvin
CEO
Patricia Colvin serves as the CEO of AI Maverick Intel, Inc., leading a team of five employees. Her background includes experience in managing small teams and guiding companies through strategic transitions, as evidenced by the company's rebranding from Bionoid Pharma Inc. to AI Maverick Intel, Inc. in April 2025. While specific details on her prior roles and educational background are not available, her leadership is focused on leveraging AI to enhance business operations within the healthcare and biotech sectors.
Track Record: Under Patricia Colvin's leadership, AI Maverick Intel, Inc. has shifted its strategic focus towards artificial intelligence, rebranding the company and developing the AI Maverick platform. Key milestones include the successful launch of the platform and the acquisition of initial clients in the healthcare and biotech sectors. However, given the company's early stage and limited financial data, it is difficult to assess her long-term track record.
AIMV OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that AI Maverick Intel, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQB or OTCQX, or of exchanges like NYSE or NASDAQ. Companies in this tier often have limited operating history, minimal assets, and may not be subject to rigorous regulatory oversight. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, manipulation, and lack of transparency. This contrasts sharply with listed exchanges that demand strict compliance and regular financial disclosures.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of publicly available financial information makes it difficult to assess the company's financial health and performance.
- Low Liquidity: Limited trading volume and wide bid-ask spreads can make it challenging to buy or sell shares.
- Potential for Fraud and Manipulation: The OTC Other tier is susceptible to fraudulent schemes and market manipulation.
- Limited Regulatory Oversight: The lack of regulatory oversight increases the risk of mismanagement and non-compliance.
- Going Concern Risk: The company's ability to continue operating as a going concern may be uncertain given its micro-cap status and limited financial resources.
- Verify the company's legal status and registration.
- Conduct a background check on the company's management team.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the company's technology and intellectual property.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Company's stated focus on AI-driven solutions.
- Rebranding to reflect strategic shift towards AI.
- Presence of a CEO (Patricia Colvin) and a small team.
- Targeting of the healthcare and biotech sectors.
- Incorporation in 2006 suggests some operating history.
AI Maverick Intel, Inc. Healthcare Stock: Key Questions Answered
What does AI Maverick Intel, Inc. do?
AI Maverick Intel, Inc. is an AI company that focuses on acquiring and enhancing businesses through its proprietary AI Maverick platform. The company's technology streamlines the customer acquisition process by automating two-way communication and enabling data-driven engagement with its clients' ideal audience segments. It primarily targets clients in the healthcare and biotech sectors, aiming to improve their operational efficiency and market reach through AI-powered tools. The company's business model centers around leveraging its AI technology to optimize various business functions, particularly in customer relationship management and data analytics.
What do analysts say about AIMV stock?
As of 2026-03-16, there is no available analyst coverage for AI Maverick Intel, Inc. due to its OTC Other listing and limited financial disclosure. Key valuation metrics such as price targets and earnings estimates are not available. Investors should conduct their own thorough research and due diligence before considering an investment in AIMV, taking into account the company's early stage, limited financial resources, and the risks associated with investing in OTC stocks. The company's growth potential depends on the successful implementation and adoption of its AI Maverick platform.
What are the main risks for AIMV?
The main risks for AI Maverick Intel, Inc. include intense competition from established technology companies, rapid technological advancements that may render the AI Maverick platform obsolete, regulatory changes in the healthcare and biotech sectors, the company's small team size and limited financial resources, and the risks associated with its OTC Other listing and lack of financial disclosure. Investors should carefully consider these risks before investing in AIMV, as they could significantly impact the company's financial performance and ability to execute its business plan.
What are the key factors to evaluate for AIMV?
AI Maverick Intel, Inc. (AIMV) holds an AI score of 58/100 (moderate). Not financial advice.
How frequently does AIMV data refresh on this page?
AIMV prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AIMV's recent stock price performance?
AI Maverick Intel, Inc. (AIMV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AI Maverick platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AIMV overvalued or undervalued right now?
Valuing AI Maverick Intel, Inc. (AIMV) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AIMV?
Before investing in AI Maverick Intel, Inc. (AIMV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC Other listing and lack of financial disclosure.
- AI analysis pending for AIMV, which may provide further insights into the company's potential.